Simulations Plus bounces after slight rev beat, maintained outlook

Shares of medical software firm Simulations Plus SLP.O last up 2.1% at $24.21 amid a sea of red on Fri after qtrly rev came in just above consensus and it reaffirmed FY outlook

SLP bounces off 1-yr low hit on Thurs by as much as 9.3% to $26.03 and is among top performers in S&P 1500 index .SPSUP, which is down 4% as equities extend losses after latest tariff salvos .N

North Carolina-based provider of simulation and modeling software for drug discovery late Thurs said fiscal Q2 rev rose 23% y/y to $22.4 mln vs LSEG estimate of $21.9 mln

Co cited 34% y/y growth in services rev, with "notable strength" in its Medical Communications unit

“We are pleased with our solid performance in the first half of the year despite the ongoing cost constrained and limited funding environment for our biopharma customers," CEO Shawn O’Connor said in the statement

Co expects to maintain momentum in the second half and reiterated fiscal 2025 guidance, including rev of $90-$93 mln with 55-60% software and 40-45% services mix

6 of 7 analysts covering SLP rate stock "strong buy" or "buy" and 1 rates "hold"; median PT of $41 down from $50 a month ago - LSEG data

With advance on the session, stock down ~13% YTD and off ~50% over the past 12 months